Korro Bio, Inc. - Common Stock (KRRO)
6.0700
-0.4300 (-6.62%)
NASDAQ · Last Trade: Nov 14th, 7:38 PM EST
Detailed Quote
| Previous Close | 6.500 |
|---|---|
| Open | 5.770 |
| Bid | 6.040 |
| Ask | 6.070 |
| Day's Range | 5.700 - 6.560 |
| 52 Week Range | 5.700 - 70.49 |
| Volume | 2,063,324 |
| Market Cap | 221.68M |
| PE Ratio (TTM) | -0.6451 |
| EPS (TTM) | -9.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 706,304 |
Chart
About Korro Bio, Inc. - Common Stock (KRRO)
Korro Bio, Inc. is a biotechnology company focused on advancing RNA-targeted therapies to treat various genetic diseases. The company develops innovative solutions leveraging its proprietary technologies aimed at delivering precise and effective treatments through the modulation of RNA. Korro Bio is dedicated to addressing unmet medical needs by harnessing the potential of RNA biology and transforming therapeutic approaches for patients suffering from serious health conditions. Through its research and development efforts, the company strives to pioneer advances in the field of precision medicine. Read More
News & Press Releases
Via Benzinga · November 13, 2025
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 13, 2025
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
Via Benzinga · November 13, 2025
Via Benzinga · November 13, 2025
Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setupstocktwits.com
Via Stocktwits · November 12, 2025
Via Benzinga · November 13, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · November 13, 2025
Via Benzinga · November 13, 2025
Korro Bio stock plummeted Thursday after its RNA-editing drug failed in patients with a rare lung and liver disease.
Via Investor's Business Daily · November 13, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · November 13, 2025
Via Benzinga · November 13, 2025
Via Benzinga · November 13, 2025
Via Benzinga · October 20, 2025
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
Via Benzinga · September 12, 2025
Via Benzinga · September 3, 2025
Via Benzinga · May 27, 2025
Via Benzinga · May 8, 2025
Via Benzinga · April 16, 2025

Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
By CAMP4 Therapeutics · Via GlobeNewswire · December 10, 2024

Via Benzinga · November 18, 2024

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.
Via Investor's Business Daily · October 21, 2024

Via Benzinga · October 16, 2024

Via Benzinga · October 16, 2024

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.
Via MarketBeat · September 22, 2024

This strategic play will take time to pay off, but it could keep growth going.
Via The Motley Fool · September 19, 2024